ClinicalTrials.Veeva

Menu

Ultrasound-Guided Erector Spinae Plan Block for Colorectal Surgery

A

Ataturk University

Status

Unknown

Conditions

Postoperative Pain
Colorectal Cancer

Treatments

Drug: Bupivacaine Hcl 0.25% infiltration
Drug: Bupivacaine Hcl 0.25% ESP block

Study type

Interventional

Funder types

Other

Identifiers

NCT04313764
ESP Colorectal Surgery

Details and patient eligibility

About

Colorectal cancer is a common and lethal disease. It still remains the third most common cause of cancer death in women and the second leading cause of death in men. Pain control is an important direction of postoperative management in malignancy surgery. Inadequate pain control increases cardiac and respiratory complications in these critical patients. Erector spinae plane (ESP) block is a recently described regional anesthesia technique that blocks the dorsal and ventral rami of the spinal nerves and the sympathetic nerve fibers. While the ESP block has been shown to provide effective postoperative analgesia after thoracic, and abdominal surgeries.

Our aim in this study was to investigate bilateral thoracic ESP block for providing successful postoperative pain management following colorectal surgery.

Enrollment

48 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • American Society of Anesthesiologist's physiologic state I-II-III patients undergoing Colorectal surgery

Exclusion criteria

  • renal or hepatic insufficiency, chronic pain, patients with an allergic reaction to anesthesia and analgesia drugs to be used

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

48 participants in 2 patient groups

Group ESPB
Active Comparator group
Description:
Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
Treatment:
Drug: Bupivacaine Hcl 0.25% ESP block
Group Infiltration
Active Comparator group
Description:
Wound infiltration with 20 ml %0.25 bupivacaine
Treatment:
Drug: Bupivacaine Hcl 0.25% infiltration

Trial contacts and locations

1

Loading...

Central trial contact

İrem Ates, MD; Ali Ahiskalioglu, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems